Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bioeqivalence study of new procaterol hydrochloride hydrate dry powder inhaler and the approved dry powder inhaler in patients with asthma: A randomised, double-blind phase III study

Next Previous
X
Search
Trial Profile

Bioeqivalence study of new procaterol hydrochloride hydrate dry powder inhaler and the approved dry powder inhaler in patients with asthma: A randomised, double-blind phase III study

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 Sep 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Procaterol (Primary)
  • Indications Asthma
  • Focus Therapeutic Use

    • Most Recent Events

    • 20 Sep 2017 New trial record
    • 01 Jan 2017 Primary endpoint of maximum FEV1 during the 480-minute measurement period has been met, according to results published in the Clinical Pharmacology in Drug Development.
    • 01 Jan 2017 Primary endpoint of area under the concentration-time curve (AUC) (FEV1)/h has been met, according to results published in the Clinical Pharmacology in Drug Development

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top